Compare Peloton Interactive Inc (PTON) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs TransMedics Group Inc — how do they compare? Peloton Interactive Inc trades at $5.11 (market cap $2.16B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Peloton Interactive Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and TransMedics Group Inc for 24 Days on average.
| PTON | TMDX | |
|---|---|---|
Market Cap | $2.16B | $2.74B |
Volume | 11,369,487 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $150.42 |
52-Week Low | $3.71 | $61.99 |
Typical Hold Time | 37 Days | 24 Days |
Enterprise Value | $2.66B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton Interactive (PTON) trades at $5.12, up 5.57% today, as the company shows signs of a turnaround with its first profitable year in 2026. Technical indicators remain bearish overall, while fundamentals reveal improving profitability with net income margin turning positive at 2.58%. Recent product launches including the foldable Tread Flex and AI-powered coaching features aim to broaden market appeal. The stock trades well below analyst consensus price target of $8.00, with 50% of analysts maintaining buy ratings despite recent insider selling activity.
PTON presents a turnaround story with improving financial metrics but faces execution risks amid declining subscriber counts. The company's debt-heavy balance sheet and negative shareholder equity remain concerns, though cash flow improvements and cost-cutting measures show progress. Upside potential exists if new product adoption drives subscriber growth, but competition and macroeconomic pressures create headwinds for sustained recovery.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
